{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:50:08Z","timestamp":1785801008952,"version":"3.56.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ejca.2018.09.008","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T12:57:10Z","timestamp":1540472230000},"page":"239-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1506-0191","authenticated-orcid":false,"given":"Christian","family":"Menzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Beedgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Rom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christin M.","family":"Duffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lena","family":"Volckmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sedlaczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Richtig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Enk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.09.008_bib1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1046\/j.1365-2133.2002.465710.x","article-title":"Applicability of reference values for the determination of serum S100 protein as a marker of malignant melanoma in children","volume":"146","author":"Hunzelmann","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2018.09.008_bib2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0025-6196(11)60669-1","article-title":"Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents","volume":"84","author":"Holtan","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2018.09.008_bib3","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1200\/JCO.2012.45.2870","article-title":"Treatment of metastatic malignant melanoma with vemurafenib during pregnancy","volume":"31","author":"Maleka","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.008_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/bdrb.21176","article-title":"An evaluation of the impact of PD-1 pathway blockade on reproductive safety of therapeutic PD-1 inhibitors","volume":"107","author":"Poulet","year":"2016","journal-title":"Birth Defects Res Part B Dev Reprod Toxicol"},{"key":"10.1016\/j.ejca.2018.09.008_bib5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1476-5381.2011.01811.x","article-title":"Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets","volume":"166","author":"Bugelski","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejca.2018.09.008_bib6","article-title":"Case report of a pregnancy during ipilimumab therapy","author":"Mehta","year":"2017","journal-title":"J Global Oncol"},{"key":"10.1016\/j.ejca.2018.09.008_bib7","first-page":"277","article-title":"New systemic agents in dermatology with respect to fertility, pregnancy, and lactation","volume":"13","author":"Grunewald","year":"2015","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft"},{"key":"10.1016\/j.ejca.2018.09.008_bib8","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2018.09.008_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2018.09.008_bib10","first-page":"1363","article-title":"Pregnancy outcomes after kidney transplantation-immunosuppressive therapy comparison","volume":"25","author":"Perales-Puchalt","year":"2012","journal-title":"J Matern Fetal Neonatal Med Off J Eur Assoc Perinat Med Fed Asia Oceania Perinat Soc Int Soc Perinat Obstet"},{"key":"10.1016\/j.ejca.2018.09.008_bib11","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1200\/JCO.2003.12.149","article-title":"Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant","volume":"21","author":"Alexander","year":"2003","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2018.09.008_bib12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jaad.2007.08.045","article-title":"Hormones, nevi, and melanoma: an approach to the patient","volume":"57","author":"Driscoll","year":"2007","journal-title":"J Am Acad Dermatol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918313789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T08:22:27Z","timestamp":1549009347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918313789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":12,"alternative-id":["S0959804918313789"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}